{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055052","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.220492+00:00","generated_at":"2026-06-02T09:18:32.577486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Syndax Q1 net loss $72.4M ($0.85/shr); revumenib NDA & axatilimab BLA under Priority Review","bullets":["Cash, equivalents and investments $522M; management believes sufficient for operations through 2026.","Revumenib NDA for R/R KMT2Ar acute leukemia granted Priority Review; PDUFA date Sep 26, 2024.","Axatilimab BLA for chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.","Enrollment completed in AUGMENT-101 mNPM1 cohort; topline data expected 4Q24, potential sNDA 1H25.","Appointed Steven Closter as Chief Commercial Officer; R&D expenses rose to $56.5M from $34.1M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055052","json":"https://secwatch.observer/filing/0000950170-24-055052.json","markdown":"https://secwatch.observer/filing/0000950170-24-055052.md","text":"https://secwatch.observer/filing/0000950170-24-055052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024055052/0000950170-24-055052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024055052/sndx-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:18:32.577486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"757de212e1f4c5ae2d37af86996a94eab3de4228","claim":"Syndax Pharmaceuticals Inc reported the quarter ended March 31, 2024 results: net income net loss attributable to common stockholders of $72.4 million, EPS $0.85 per share.","evidence_excerpt":"Syndax reported a net loss attributable to common stockholders of $72.4 million, or $0.85 per share, compared to a net loss attributable to common stockholders of $41.1 million, or $0.59 per share, for the comparable prior year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024055052/0000950170-24-055052-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"net loss attributable to common stockholders of $72.4 million"},{"label":"EPS","value":"$0.85 per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}